#cancer epigenome

[a-typical]

Scientists Have Reached a Key Milestone in Learning How to Reverse Aging

Loss of epigenetic information as a cause of mammalian aging

Scientists Have Reached a Key Milestone in Learning How to Reverse Aging

Highlights from the Study

Cellular responses to double-stranded DNA breaks erode the epigenetic landscape

This loss of epigenetic information accelerates the hallmarks of aging

These changes are reversible by epigenetic reprogramming

By manipulating the epigenome, aging can be driven forward and backward

“Underlying aging is information that is lost in cells, not just the accumulation of damage,” says Dr. David Sinclair, a professor of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. His latest results seem to support that theory.

All living things experience entropy manifested as a loss of genetic and epigenetic information. Genetic information is the hardware and the epigenome is the software. We think aging is due to corrupted software, that can be rebooted to restore youth.

It’s similar to the way software programs operate off hardware, but sometimes become corrupt and need a reboot. But by showing that we can reverse the aging process, that shows that the system is intact, that there is a backup copy and the software needs to be rebooted.”

In the mice, he and his team developed a way to reboot cells to restart the backup copy of epigenetic instructions, essentially erasing the corrupted signals that put the cells on the path toward aging. They mimicked the effects of aging on the epigenome by introducing breaks in the DNA of young mice. - Once “aged” in this way, within a matter of weeks Sinclair saw that the mice began to show signs of older age—including grey fur, lower body weight despite unaltered diet, reduced activity, and increased frailty.

The rebooting came in the form of a gene therapy involving three genes that instruct cells to reprogram themselves— These genes came from the suite of so-called Yamanaka stem cells factors—a set of four genes that Nobel scientist Shinya Yamanaka in 2006 discovered can turn back the clock on adult cells to their embryonic, stem cell state so they can start their development, or differentiation process, all over again. Sinclair didn’t want to completely erase the cells’ epigenetic history, just reboot it enough to reset the epigenetic instructions. Using three of the four factors turned back the clock about 57%, enough to make the mice youthful again.

Using a system called “ICE” (Inducible Changes to the Epigenome), we show the act of repairing DNA breaks accelerates aging at the physiological, cognitive, & molecular levels, including erosion of the epigenetic landscape, loss of cell identity, senescence & increased epi-age ... "We show these changes can be reversed by OSK-mediated rejuvenation. With an ability to drive aging in both the forward and reverse directions, we conclude that loss of epigenetic information is a cause of aging in mammals."

“We haven’t found a cell type yet that we can’t age forward and backward.”

In 2020, Sinclair reported that in mice, the process restored vision in older animals; the current results show that the system can apply to not just one tissue or organ, but the entire animal. He anticipates eye diseases will be the first condition used to test this aging reversal in people, since the gene therapy can be injected directly into the eye area.

"If correct, it means that cancer, diabetes and Alzheimer's might have the same underlying cause that can be reversed to treat or cure age-related conditions with a single treatment. Experiments in the lab are testing this."

Even before that happens, the process could be an important new tool for researchers studying these diseases.

"The age-reversal technology -- virally-delivered genes (Oct4, Sox2, Klf4, aka, Yamanaka factors), which turn on an embryonic program -- is being tested at @lifebiosciences in non-human primates. Results out in a few months from Bruce Ksander's lab & http://lifebiosciences.com"

[rameshindustryarc]

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦𝐬: 𝐇𝐨𝐰 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐜𝐞𝐬 𝐆𝐞𝐧𝐞 𝐄𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐄𝐱𝐩𝐥𝐚𝐢𝐧𝐞𝐝-IndustryARC™

Epigenetics Market Size is forecast to reach $ 5,115.20 Million by 2030, at a CAGR of 17.50% during forecast period 2024-2030.

📊 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞

#Epigenetics is the study of changes in gene activity that

don't involve alterations to the genetic code itself. These changes can be

influenced by various factors such as environment, lifestyle, and experiences.

They can impact gene expression and, consequently, traits and health outcomes.Understanding epigenetics is crucial for unraveling complex interactions between nature and nurture in shaping an organism's development and susceptibility to diseases.

The epigenetics market is experiencing exponential growth fueled by advancements in technology. The latest methods, such as #CRISPR-based #epigenome editing, are revolutionizing research and applications. These breakthroughs enable precise manipulation of gene expression, offering unprecedented insights into diseases, aging, and personalized medicine. As demand surges for innovative solutions, the epigenetics market is poised for substantial expansion and transformative impact.

The recognition of epigenetic modifications as viable targets for drug discovery is propelling market growth. Pharmaceutical firms are heavily investing in epigenetic research to develop groundbreaking therapies. For instance, in cancer treatment, drugs such as Azacitidine and Decitabine, which target #DNA methylation, have revolutionized therapy options,demonstrating the market's potential. Similarly, research into epigenetic therapies for neurological disorders and autoimmune diseases is accelerating,further driving market expansion.

[jobrxiv]

Postdoc Position - Investigating Tumor Heterogeneity German Cancer Research Center 2 Postdoc positions in tumor heterogeneity (wet-lab or dry-lab) See the full job description on jobRxiv: https://jobrxiv.org/job/german-cancer-research-center-27778-postdoc-position-investigating-tumor-heterogeneity/?feed_id=86822 #cancer_genomics #epigenomics #immunotherapy #precision_oncology #sarcoma #translational_research #tumor_microenvironment #ScienceJobs #hiring #research

[businessmarketreports]

An Overview of Next Generation Sequencers Market: Trends and Insights

The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.

Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report

This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.

1. Market Overview

Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.

Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.

Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.

2. Key Trends in the NGS Market

Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.

Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.

Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.

Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.

Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.

Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.

3. Market Segmentation

By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.

By Technology:

Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.

Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.

RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.

Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.

By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.

By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.

4. Key Drivers and Challenges

Drivers:

Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.

Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.

Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.

Challenges:

Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.

Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.

High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.

5. Competitive Landscape

The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.

Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.

Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.

Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.

Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.

BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.

Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.

Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.

6. Future Outlook

Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.

Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.

Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.

Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.

Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.

Conclusion

The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.

[abhilashnale]

Colorectal Cancer Screening Market Global Insights: Business Demand, Top Leading Players, and Precise Outlook with Future Scope, Forecast by 2032

The Evolutionary Path of the Colorectal Cancer Screening Market

The global Colorectal Cancer Screening market has emerged as a focal point for businesses, offering a plethora of opportunities and challenges. As industries navigate this landscape, understanding its evolution becomes crucial for strategic planning and decision-making.

According to Straits Research, the global colorectal cancer screening market size was valued at USD 13734.03 Million in 2022. It is projected to reach from USD XX Million in 2023 to USD 26441.8 Million by 2031, growing at a CAGR of 7.55% during the forecast period (2023–2031).

Historically, the Colorectal Cancer Screening market has witnessed significant transformations, driven by technological innovations, regulatory changes, and shifting consumer preferences. These shifts have not only reshaped the market landscape but also presented businesses with new avenues for growth and innovation.

Note: We're in the process of updating our reports. If you're seeking updated primary and secondary data from 2023-2031, coupled with insights on Cost Module, Business Strategy, and Competitive Landscape, kindly click ""request free sample report."" The comprehensive report will reach you via email within 24 to 48 hours.

Get Access to a Free Copy of Our Latest Sample Report@https://straitsresearch.com/report/colorectal-cancer-screening-market/request-sample

Companies and Manufacturers Covered:

Key market players play a pivotal role in shaping the market narrative. By profiling industry leaders and their strategic initiatives, the report offers insights into competitive dynamics and market trends. These insights are invaluable for businesses seeking to gain a competitive edge and capitalize on emerging opportunities.

Clinical Genomics Technologies Pty Ltd

Epigenomics AG

Exact Sciences Corporation

Hemosure Inc

Novigenix SA

Quidel Corporation

Siemens Healthcare Private Limited

Sysmex Corporation

Eiken Chemical Co. Ltd

Polymedco Inc

Olympus Corporation

A recent market analysis provides a comprehensive overview of the Global Colorectal Cancer Screening Market, highlighting key growth drivers and emerging trends. This report serves as a valuable resource for businesses, offering insights into the market dynamics, competitive landscape, and growth prospects.

Buy this Premium Research Report@https://straitsresearch.com/buy-now/colorectal-cancer-screening-market

The quantitative analysis accompanying the report offers a decade-long perspective on the market's trajectory. By examining historical data and forecasting future trends, stakeholders can gain a deeper understanding of market dynamics and make informed decisions.

Global Regional Outlook:

North America: North America is currently the largest market for Colorectal Cancer Screening, accounting for a significant share of the global market.

Asia Pacific: While the North America leads in market size, Asia Pacific is emerging as the fastest growing region in the Colorectal Cancer Screening market.

Research Methodology

The research methodology employed in curating this report is rigorous and comprehensive. By leveraging both primary and secondary data sources, the report ensures accuracy and reliability. Through interviews with industry experts, analysis of annual reports, and examination of Colorectal Cancer Screening market trends, the report offers a holistic view of the market landscape.

Market Segmentation:

By Screening Tests

Stool-Based Tests

Colonoscopy

Ct Colonography (Virtual Colonoscopy)

Flexible Sigmoidoscopy

By End-User

Hospitals

Independent Diagnostic Labs

Ask Here For More Customization Study@https://straitsresearch.com/report/colorectal-cancer-screening-market/toc

Report Features:

Actionable market intelligence for strategic decision-making

Comprehensive forecasts spanning 2018 - 2031

In-depth growth trend assessments

Segment-specific and regional revenue projections

Competitive analysis and market share insights

Innovative product listings for competitive advantage

Insights into the market implications of COVID-19

Report availability in various formats: PDF, XLS, PPT, and digital dashboards

In conclusion, the global Colorectal Cancer Screening market offers a dynamic and evolving landscape for businesses. By staying abreast of market trends, leveraging data-driven insights, and adopting a strategic approach, businesses can navigate this landscape successfully and drive growth.

Report Customization:

Our report is adaptable to your specific needs. For tailored insights, please reach out to our sales team at sales@straitsresearch.com. Additionally, you can contact our representatives directly at +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.) to discuss your research criteria.

[shubhampawrainfinium]

A New Dimension of Biology: The Rise of Single Cell Multiomics

The global single cell multiomics market is experiencing significant growth, driven by advancements in biotechnology and the rising demand for precision medicine. According to the report, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 18% during the forecast period of 2022-2028. In 2022, the global single cell multiomics market was valued at around USD 3.5 billion, and it is expected to reach nearly USD 9.5 billion by 2028.

What is Single Cell Multiomics?

Single cell multiomics is an advanced analytical approach that studies individual cells by combining multiple 'omics' platforms, such as genomics, transcriptomics, proteomics, and epigenomics. This method provides a comprehensive understanding of the cellular functions and the underlying molecular mechanisms. By analyzing a single cell's DNA, RNA, proteins, and epigenetic markers, researchers can uncover unique insights into cellular heterogeneity and disease mechanisms that are not possible with bulk cell analysis.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/35323

Market Dynamics and Growth Drivers

Several factors are contributing to the rapid growth of the global single cell multiomics market:

Rising Demand for Precision Medicine: Precision medicine aims to tailor medical treatments to individual patients based on their genetic and molecular profile. Single cell multiomics plays a pivotal role in this approach by providing detailed insights into individual cells, enabling better understanding and treatment of complex diseases such as cancer, neurodegenerative disorders, and autoimmune diseases.

Technological Advancements: Advances in next-generation sequencing (NGS), mass spectrometry, and bioinformatics have made it easier and more cost-effective to conduct single cell multiomics studies. These innovations are driving adoption across academic and clinical research settings, allowing for more comprehensive analysis of cellular functions.

Growing Focus on Cancer Research: Cancer research is one of the primary applications of single cell multiomics, as it helps to decipher tumor heterogeneity, drug resistance, and tumor microenvironments at the single-cell level. The growing prevalence of cancer globally is fueling the demand for single cell multiomics in oncology research.

Increased Government and Private Funding: Governments and private organizations are investing heavily in genomics and precision medicine initiatives, providing funding and grants to support research in single cell analysis. These efforts are expected to boost market growth during the forecast period.

Regional Analysis

North America: North America holds the largest share of the global single cell multiomics market, primarily driven by the region’s advanced healthcare infrastructure, significant investment in precision medicine, and the presence of key market players. The United States, in particular, is a hub for genomics research, with major academic and research institutions adopting single cell technologies.

Europe: Europe is another prominent market for single cell multiomics, with countries like the U.K., Germany, and France at the forefront of multiomics research. The region’s robust research landscape, coupled with government initiatives supporting genomics research, is contributing to market growth.

Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing investments in biotechnology and healthcare research in countries like China, Japan, and India. Growing awareness about precision medicine and improving healthcare infrastructure are also key factors driving market expansion in this region.

Rest of the World: While the adoption of single cell multiomics is still in its early stages in regions like Latin America and the Middle East & Africa, growing interest in genomics and personalized medicine is expected to create future growth opportunities.

Competitive Landscape

The global single cell multiomics market is highly competitive, with several key players actively contributing to advancements in the field. Major companies include:

10x Genomics: A leader in single cell sequencing technologies, offering solutions that enable comprehensive single cell multiomics analysis for research and clinical applications.

Illumina, Inc.: A major player in the genomics space, providing sequencing platforms and technologies that support single cell analysis and multiomics studies.

Fluidigm Corporation: Specializes in developing single cell proteomics and genomics platforms, helping researchers investigate cellular heterogeneity and molecular interactions.

Becton, Dickinson and Company (BD): Offers innovative solutions for single cell multiomics, including platforms for high-dimensional proteomics and transcriptomics.

QIAGEN: Known for its sample preparation and bioinformatics solutions, QIAGEN supports multiomics research by enabling comprehensive data analysis and integration.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-single-cell-multiomics-market

Challenges and Opportunities

Despite its promising growth, the single cell multiomics market faces several challenges. High costs associated with single cell technologies and data analysis, as well as the complexity of multiomics data interpretation, may hinder widespread adoption, particularly in resource-constrained regions. Additionally, the integration of multiple 'omics' datasets and the lack of standardized protocols pose technical challenges.

However, there are substantial opportunities for growth. Continuous advancements in technology, decreasing costs of sequencing, and the growing adoption of artificial intelligence (AI) and machine learning (ML) for data analysis are expected to drive market expansion. Furthermore, as researchers uncover more insights into cellular heterogeneity, new applications of single cell multiomics in disease research, drug development, and personalized medicine are likely to emerge.

Conclusion

The global single cell multiomics market is poised for robust growth, with a projected CAGR of nearly 18% from 2022 to 2028. This market's expansion is fueled by increasing demand for precision medicine, advancements in biotechnology, and growing research applications in cancer and drug development. As the field of single cell multiomics continues to evolve, it holds the potential to revolutionize healthcare by enabling more accurate diagnostics, personalized treatments, and a deeper understanding of complex diseases.

[opinionated-opinion]

The Role of Epigenetic Modifications in Gene Regulation: A Critical Review Cellular differentiation, development, and response to various environmental changes all are multistep biological processes that depend fundamentally on gene regulation. Epigenetic modifications allow the cell to respond interactively to environmental changes without altering the DNA sequence and have thus gained increased attention during the last few years. This blog will critically review some of the important epigenetic mechanisms-DNA methylation, histone modifications, and noncoding RNAs-and their involvement in health and disease.

What is Epigenetic? Epigenetics is defined as the study of heritable features concerning the role of gene regulation and not the underlying DNA sequence. These types of modification, usually reversible, have the ability to dynamically alter the expression of a gene by a cell. The epigenetic mechanisms allow cell differentiation in multicellular organisms beginning from the same DNA sequence genome.

Key Mechanisms of Epigenetic Regulation

DNA Methylation

DNA Methylation DNA methylation is one among the well-studied epigenetic mechanisms. It comprises the addition of a methyl group to the cytosine residue in the CpG dinucleotides, usually associated with the silencing of gene expression. Methylation patterns are important in normal development, while abnormal methylation is associated with diseases including cancer. For instance, the hypermethylation of tumor suppressor genes has been related to the inactivation of such genes in many kinds of cancers Esteller 2007.

Histone Modifications

DNA wraps around core histone proteins to form a nucleoprotein called chromatin, and changing the tail domains of the histones affects both the structure of chromatin and gene expression. Acetylation, methylation, phosphorylation, and sumoylation of histones affects the access of DNA to the transcriptional machinery. For example, in general, histone acetylation activates transcription whereas deacetylation causes silencing, Kouzarides 2007.

Non-coding RNAs: ncRNAs Non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), also play significant roles in gene regulation. miRNAs can degrade messenger RNA (mRNA) or inhibit translation, thus controlling gene expression post-transcriptionally. lncRNAs, on the other hand, regulate gene expression at various levels, including chromatin modification, transcription, and post-transcriptional processes (Rinn & Chang, 2012).

Critical Review: Epigenetic Changes Are of a Janus Nature Epigenetic modification is an indispensable component in physiological processes but turns out to be a double-edged sword since inappropriate epigenetic change gives rise to diseases like tumorigenesis, neurodegeneration, and autoimmune disease.

Epigenetic Therapies Epigenetic alterations, due to their reversible nature, represent very promising therapeutic targets. Therapeutic drugs like DNA methyltransferase inhibitors (for example, azacitidine) and histone deacetylase inhibitors (for example, vorinostat) are effective in the treatment of some cancers (Jones et al., 2016). However, the main challenges lie in guaranteeing specificity because broad epigenetic reprogramming leads to off-target effects.

Epigenetic and Environmental Influence The epigenome is very sensitive to nutrition, toxicants, and stresses. For example, prenatal exposure to malnutrition results in epigenetic modification, increasing the susceptibility to metabolic diseases later in life (Heijmans et al., 2008). Such sensitivities underline how understanding of epigenetic regulation involves lifestyle factors.

Conclusion:

Epigenetic modifications also play crucial roles in fine-tuning gene expression and the maintenance of cellular homeostasis. While allowing new possibilities of therapeutic intervention, especially in cancer, some problems remain to be investigated concerning specificity and also environmental impact. Further research will thus become necessary regarding the dynamic nature of the epigenome if specific and efficacious treatments are to be developed.

References

Esteller, M. (2007). Epigenetic gene silencing in cancer: The DNA hypermethylome. Human Molecular Genetics, 16(R1), R50–R59.

Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susser, E. S., Slagboom, P. E., & Lumey, L. H. (2008). Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proceedings of the National Academy of Sciences, 105(44), 17046-17049.

Jones, P. A., Issa, J. P., & Baylin, S. (2016). Targeting the cancer epigenome for therapy. Nature Reviews Genetics, 17(10), 630–641.

Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693-705.

Rinn, J. L., & Chang, H. Y. (2012). Genome regulation by long noncoding RNAs. Annual Review of Biochemistry, 81, 145-166.

[evoldir]

Fwd: Conference: Vienna.PopGen.SeminarWinterSchedule

Begin forwarded message: > From: evoldir@evol.biology.mcmaster.ca > Subject: Conference: Vienna.PopGen.SeminarWinterSchedule > Date: 19 September 2024 at 06:47:45 BST > To: rdmpage@gmail.com > > > Dear colleagues, > > The Vienna Graduate School of Population Genetics runs an internationally > recognized seminar series featuring weekly talks by leading experts in > population genetics. > > We invite interested viewers to stream the seminars during the upcoming > winter term (Tuesdays at 17:00 CET/CEST). Sign up here to receive weekly > streaming links (Webex): https://ift.tt/azPvn0F > > Schedule and updates are listed on our website: > https://ift.tt/ZFkIm0h > > Many talks are posted to YouTube: > https://www.youtube.com/@popgenvienna8051 > > Winter term schedule: > > 08.10.24 – Lara Radovic (Vetmeduni, AT) > > Y chromosome enlightens the last 1,500 years of horse history. > > 15.10.24 – Rasmus Nielsen (Univ. of California, Berkeley, US) > Ancestral Recombination Graphs and their use for population genetic > inferences. > > 22.10.24 – Patrick Tschopp (Univ. of Basel, CH) > > Cell fate convergence in the vertebrate skeleton. > > 29.10.24 – Ann-Marie Waldvogel (Univ. of Cologne, DE) > Understanding ecological impact on genome evolution – from rivers > to deserts. > > 05.11.24 – Aurelien Tellier (TU Munich, DE) > Inference of past demography and life-history traits from genomic and > epigenomic polymorphism data. > > 12.11.24 – Nandita Garud (Univ. of California, Los Angeles, US) > > Inference of demography and selection from human gut commensal microbiota. > > 19.11.24 – Ralf Sommer (Max Planck Inst. for Developmental Biology, DE) > What’s wrong with evolutionary theory? > > 26.11.24 – Alexander Suh (Univ. of East Anglia, UK) > Unusual inheritance and evolution of the germline-restricted chromosome > of songbirds. > > 03.12.24 – Mario dos Reis (Queen Mary Univ. of London, UK) Modeling > the action of natural selection on protein-coding genes. > > 10.12.24 – Rhonda Snook (Stockholm Univ., SE) Ecological and > evolutionary consequences of reproductive stress in insects. > > 17.12.24 – Katie Lotterhos (Northeastern Univ., US) Inversions as > concentrators of polygenic architectures. > > 14.01.25 – Martin Kaltenpoth (Max Planck Inst. For Chemical Ecology, > DE) Microbial symbionts as sources of evolutionary innovations in beetles. > > 21.01.25 – George Cresswell (St. Anna Kinderkrebsforschung, AT) Cancer > Evolution: Basic principles to clinical implications. > > 28.01.25 – Simon Martin (Univ. of Edinburgh, UK) Chromosomal > rearrangements and local adaptation: more than meets the eye. > > Sincerely, > > Carina Baskett > > Coordinator, Joint Research Program (SFB)--Polygenic Adaptation > Coordinator, Vienna Graduate School of Population Genetics > she/her/hers > carina.baskett@vetmeduni.ac.at > > Baskett Carina

[rnomics]

Genes, Vol. 15, Pages 1161: Simultaneous Visualization of R-Loops/#RNA:DNA Hybrids and Replication Forks in a DNA Combing Assay

R-loops, structures that play a crucial role in various biological processes, are integral to gene expression, the maintenance of genome stability, and the formation of epigenomic signatures. When these R-loops are deregulated, they can contribute to the development of serious health conditions, including #cancer and neurodegenerative diseases. The detection of R-loops is a complex process that involves several approaches. These include S9.6 antibody- or #RNAse H-based immunoprecipitation, non-denaturing bisulfite footprinting, gel electrophoresis, and electron microscopy. Each of these methods offers unique insights into the nature and behavior of R-loops. In our study, we introduce a novel protocol that has been developed based on a single-molecule DNA combing assay. This innovative approach allows for the direct and simultaneous visualization of #RNA:DNA hybrids and replication forks, providing a more comprehensive understanding of these structures. Our findings confirm the transcriptional origin of the hybrids, adding to the body of knowledge about their formation. Furthermore, we demonstrate that these hybrids have an inhibitory effect on the progression of replication forks, highlighting their potential impact on DNA replication and cellular function. https://www.mdpi.com/2073-4425/15/9/1161?utm_source=dlvr.it&utm_medium=tumblr

[poonamcmi]

Colorectal Cancer Screening Market Primed for Growth due to Rising Disease Prevalence

The colorectal cancer screening market involves various procedures and diagnostic tests for early detection and prevention of colorectal cancer. Some common screening methods include fecal occult blood tests, flexible sigmoidoscopy, double-contrast barium enema, and colonoscopy. Colorectal cancer screening helps detect precancerous polyps or early stage cancer that can often be treated successfully. It also aids in lowering the incidence and mortality of this preventable disease.

The global colorectal cancer screening market is estimated to be valued at US$ 15.44 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the colorectal cancer screening market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Exact Sciences Corporation, Clinical Genomics, Guardant Health, Inc., Hemosure Inc., and Geneoscopy, Inc. These players are focused on launching advanced and easy-to-use screening tests to expand their presence.

The Colorectal Cancer Screening Market Size for players to leverage the growing awareness about early detection and increase screening rates in developing countries. Companies are engaging in partnerships and collaborations to penetrate developing markets and make screening accessible to a wider population.

Globally, there is an increasing focus on population-based screening programs to reduce the burden of colorectal cancer. Several regions have implemented organized screening programs through healthcare facilities. Meanwhile, growing pilot programs in Asian and Latin American countries indicate the potential for market expansion. Market Drivers

The rapid rise in colorectal cancer incidence worldwide due to lifestyle changes, obesity, and Colorectal Cancer Screening Market Size And Trends It is estimated that the number of new cases diagnosed each year will increase by 60% by 2030. Growing disease prevalence enhances the need for widespread screening practices to detect cancer at treatable stages. Additionally, increasing reimbursement for FDA-approved screening tests, favorable government initiatives, and rising awareness about early detection are supporting the adoption of screening worldwide. PEST Analysis Political: Government regulations and healthcare reforms impact the adoption of colorectal cancer screening tests. Favorable reimbursement policies can boost the market growth. Economic: Rising healthcare expenditures and growing disposable incomes encourage people to opt for preventive healthcare check-ups including colorectal cancer screening tests. Social: Increasing awareness about early detection benefits, changing lifestyles, and growing geriatric population drive the demand for colorectal cancer screening. Technological: Advancements in biopsy techniques, endoscopy devices, diagnostic platforms enable detection of colorectal cancer at an early stage. Novel non-invasive tests based on blood, stool and CSF analysis are gaining traction.

Colorectal cancer screening market in terms of value is highly concentrated in developed regions like North America and Western Europe due to established healthcare infrastructure and widespread awareness. The United States dominates the market owing to favorable reimbursement policies and regular screening recommendations.

Asia Pacific is recognized as the fastest growing regional market for colorectal cancer screening attributed to rising healthcare spending, growing number of screening programs, and increasing incidence of colorectal cancer cases especially in China, Japan and India. Improving diagnostic capabilities and economic development are expected to boost early detection in Asia Pacific over the forecast period. Get More Insights On, Colorectal Cancer Screening Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163

[shrutirathi226]

The Role of Single-Cell Omics in Unraveling Complex Disease Mechanisms

The introduction of single-cell omics technology is a revolutionary step in the field of biological study. A variety of methods aimed at examining the molecular profiles of individual cells are referred to as “single-cell omics,” which provides before unattainable insights into cellular functioning and heterogeneity that were hidden in bulk investigations. With amazing accuracy, researchers can now uncover the intricacies of biological systems thanks to this method.

Single-Cell Omics: What Is It?

The study of genomic, transcriptomic, proteomic, and epigenomic data at the level of individual cells is known as single-cell omics. Single-cell omicsexamines the subtle changes between individual cells within a tissue or organism, in contrast to typical omics methodologies that study pooled cells and so disguise individual cell variations. Understanding how cells contribute to the overall variety and functionality of biological systems requires this level of detail.

Advances in Technology

Single-cell technology developments recently have completely changed the area. Researchers may quantify the gene expression patterns of individual cells using single-cell RNA sequencing (scRNA-seq), which reveals the dynamic and varied nature of gene activity. Comparably, single-cell DNA sequencing offers information on cellular genetic variants and mutations that are critical to comprehending cancer and other hereditary illnesses. These skills are further enhanced by single-cell proteomics and epigenomics, which provide single-cell resolution protein and epigenetic modification analysis.

Uses and Consequences

Single-cell omics has several significant uses. Single-cell sequencing has shown heterogeneity within tumors in cancer research, revealing subpopulations of cancer cells that could be involved in resistance and the advancement of the illness. Single-cell omics provides insights into how stem cells differentiate into different types of cells by tracing the cellular lineage in developmental biology. Single-cell investigations are useful in neurobiology because they map the variety of neuronal cell types and their roles in both healthy and diseased brains.

Furthermore, single-cell omics is essential for comprehending microbial populations, immunological responses, and complicated illnesses. Through analyzing the cellular makeup of these systems, scientists can discover disease causes and find new targets for treatment.

Obstacles and Prospects for the Future

Even with its revolutionary promise, single-cell omics has a number of drawbacks. Because of the intricacy of the data produced, analysis and interpretation need sophisticated computing techniques. Furthermore, a barrier to the general adoption of single-cell technologies may be their high cost and technical requirements.

Further insights might be obtained by combining single-cell omics with other high-throughput methods and cutting-edge technology. It is anticipated that developments in computational techniques, data integration, and technological downsizing would improve single-cell omics’ usability and accessibility across a range of study domains.

In summary

At the vanguard of biological study, single-cell omics provides an intricate and nuanced perspective of cellular dynamics that is unmatched by bulk analysis. The insights gleaned from single-cell omics will surely increase our knowledge of complex biological systems and aid in the development of targeted therapeutics and personalized medicine as technology and methodology continue to progress.

[sa7abnews]

FDA approves new blood test for colon cancer screening: ‘Early detection is critical’

New Post has been published on https://sa7ab.info/2024/08/09/fda-approves-new-blood-test-for-colon-cancer-screening-early-detection-is-critical/

FDA approves new blood test for colon cancer screening: ‘Early detection is critical’

Screening for the second leading cause of cancer deaths just got a bit easier.The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).Shield, made by Guardant Health in California, is the first approved blood test that is considered a primary screening option for the disease and meets Medicare coverage requirements, the company stated.WHAT IS COLORECTAL CANCER? SIGNS, SYMPTOMS, RISKS AND MORE OF THE GLOBAL HEALTH CONCERNThe FDA’s approval, announced Tuesday, follows a large clinical trial that included 20,000 average-risk adults, which found that Shield had an 83% sensitivity for the detection of CRC.Those findings were published in The New England Journal of Medicine in March.There is another approved blood test, Epigenomics’ Epi proColon, but it is a second-line screening option, which means it can only be given to patients who have been offered first-line options and have a history of not completing CRC screening, according to Michael Weist, a spokesperson from Guardant Health.Robert Smith, PhD, senior vice president of Early Cancer Detection Science for the American Cancer Society in Atlanta, confirmed that Shield is the only blood test currently available for colorectal cancer screening. TRAGIC CANCER LOSS INSPIRES NEW YORK TECH ENTREPRENEUR TO ADDRESS ‘URGENT MEDICAL NEED’”It compares favorably with other colorectal cancer screening tests,” such as colonoscopy, CT colonography and stool tests, Smith, who is not affiliated with Guardant, told Fox News Digital.”The test … likely will be more appealing to people who have never been screened, or not recently screened,” he added.The key advantage of the blood test is that it can be done during a routine doctor’s appointment without the need for prepping or taking an entire day off from work.”It offers the potential to detect colorectal cancer in a person who is non-adherent with screening recommendations, asymptomatic and willing to get this test based on preference, convenience or both,” Smith said.Shield has shown “reasonable sensitivity and specificity compared to other blood/stool tests,” according to Dr. Shuji Ogino, chief of the Molecular Pathological Epidemiology program at Brigham and Women’s Hospital, which is a member of Mass General Brigham in Boston.”Compared to colonoscopy, it is simpler and less time-consuming,” Ogino, who is not associated with Guardant, told Fox News Digital.While the risks of the Shield test have not been studied in a population of regular users, they are likely to be minimal, according to ACS’ Smith. “However, the Shield test does not offer the same level of benefit to prevent colorectal cancer by detecting and removing precursor lesions (polyps), which is a significant benefit from regular screening with the currently recommended tests,” Smith cautioned.That downside would be offset by more unscreened people choosing to get screenings, he noted.”The Shield blood test does have a lower degree of sensitivity than the Cologard stool test for detecting colon cancer,” Stephen Grabelsky, M.D., a hematologist and medical oncologist at the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, told Fox News Digital.The test is only intended for people with a standard risk for colon cancer, which excludes patients with a family history of colon cancer or a personal history of inflammatory bowel disease, Grabelsy added. (He also was not involved in the test’s development.)The compliance rate for colorectal cancer screenings is only about 59% — well below the National Colorectal Cancer Roundtable’s goal of 80% for eligible individuals, according to Weist.”More than one out of three eligible Americans – over 50 million people – do not complete CRC screenings, often due to the perception that other available options, such as colonoscopies or stool-based tests, are invasive, unpleasant or inconvenient,” he said. When detected early, colon cancer has a relative survival rate of 91% — compared to just 14% if the cancer has spread to distant parts of the body. “Early detection is critical,” Weist said. “The most effective screening test is the test that gets done.”CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTERThe Shield test is indicated for colorectal cancer screening in individuals age 45 and older who have an average risk for the disease, he told Fox News Digital. The test is expected to be commercially available by this fall. Patients interested in the Shield test should discuss the benefits and limitations with a health care provider before making a choice, Smith recommended, and should also determine whether their insurance will cover it. “It is important to appreciate that a colorectal cancer screening test that is positive is not complete until the patient has had a colonoscopy,” Smith noted.For more Health articles, visit www.foxnews/health”Any non-colonoscopy screening test for colorectal cancer that is positive must be followed up with a colonoscopy.”

[credenceresearchdotblog]

The nucleic acid isolation and purification market is indeed poised for substantial growth, with an anticipated value of USD 10.10 billion by 2032, reflecting a notable compound annual growth rate (CAGR) of 9.11% from USD 4.22 billion in 2023.The nucleic acid isolation and purification market is experiencing substantial growth, driven by advancements in biotechnology and increased research investments. This market encompasses a range of technologies and methodologies designed to extract and purify nucleic acids—DNA and RNA—from biological samples, which are essential for various applications in research, diagnostics, and therapeutics.

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-isolation-and-purification-market

Market Overview

Nucleic acid isolation and purification are critical processes in molecular biology, genomics, and personalized medicine. These processes enable scientists and researchers to study genetic material with high precision, paving the way for breakthroughs in disease understanding, drug development, and clinical diagnostics. The market for these technologies is expanding due to the growing demand for high-quality nucleic acid samples and the increasing prevalence of genetic disorders and cancer.

Market Drivers

1. Advancements in Biotechnology: The rapid progress in genomic technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), has spurred demand for reliable and efficient nucleic acid isolation and purification methods. These advancements are crucial for obtaining high-quality samples needed for accurate genomic analysis.

2. Rising Prevalence of Genetic Disorders: With the increasing incidence of genetic disorders and cancer, there is a heightened demand for genetic testing and personalized medicine. Accurate nucleic acid extraction and purification are essential for reliable diagnostic results and tailored treatment strategies.

3. Growing Research and Development Activities: Continuous research in fields like genomics, transcriptomics, and epigenomics requires advanced nucleic acid isolation and purification techniques. The proliferation of research activities in these areas contributes to the market's growth.

4. Technological Innovations: The development of automated systems and high-throughput platforms has enhanced the efficiency and scalability of nucleic acid isolation and purification processes. Innovations such as magnetic bead-based purification and microfluidic devices are driving market expansion.

Market Segmentation

The nucleic acid isolation and purification market can be segmented based on technology, product type, application, and end-user:

1. By Technology: Key technologies include column-based methods, magnetic bead-based methods, and gel electrophoresis. Magnetic bead-based methods are gaining popularity due to their high sensitivity and automation capabilities.

2. By Product Type: This segment includes kits, reagents, and instruments. Kits, which offer convenience and comprehensive solutions, dominate the market. Reagents and instruments are also essential components, with continuous innovation driving their adoption.

3. By Application: The primary applications are in research and development, diagnostics, and therapeutics. Research and development hold the largest share, driven by the need for genomic and transcriptomic studies.

4. By End-User: End-users include academic and research institutions, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. Academic and research institutions are significant contributors to the market due to their extensive research activities.

Regional Analysis

The nucleic acid isolation and purification market exhibits diverse trends across regions:

1. North America: The North American market is the largest, driven by the presence of major biotechnology firms, advanced research facilities, and significant investments in healthcare research.

2. Europe: Europe is also a major market, with a strong emphasis on research and development and a growing focus on personalized medicine. Countries like Germany and the UK are key contributors.

3. Asia-Pacific: The Asia-Pacific region is witnessing rapid growth due to increasing investments in research and development, expanding healthcare infrastructure, and a rising number of biotechnology firms. Countries like China and India are emerging as prominent players.

4. Latin America and the Middle East & Africa: These regions are experiencing steady growth, driven by improving healthcare infrastructure and increasing research activities.

Challenges and Future Outlook

Despite the market's growth, there are challenges such as high costs of advanced technologies and the need for skilled personnel. However, the ongoing development of cost-effective solutions and user-friendly platforms is expected to address these issues.

Looking ahead, the nucleic acid isolation and purification market is poised for continued growth, fueled by technological advancements, increasing research activities, and rising demand for genetic testing. The integration of artificial intelligence and machine learning in these processes is likely to further enhance efficiency and accuracy.

Key player:

QIAGEN N.V.

Thermo Fisher Scientific Inc.

Illumina Inc.

Danaher Corporation

Hoffmann La Roche Ltd

Merck KGaA

Agilent Technologies Inc.

Bio-Rad Laboratories

Takara Bio Inc.

Promega Corporation

New England Biolabs

Abcam plc.

PCR Biosystems

Segments:

By Product:

Kits

Reagents

Instruments

By Application:

Plasmid

DNA

RNA

By End User:

Pharmaceutical Companies

Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

By Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/nucleic-acid-isolation-and-purification-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[jobrxiv]

Postdoc Position - Investigating Tumor Heterogeneity German Cancer Research Center 2 Postdoc positions in tumor heterogeneity (wet-lab or dry-lab) See the full job description on jobRxiv: https://jobrxiv.org/job/german-cancer-research-center-27778-postdoc-position-investigating-tumor-heterogeneity/?feed_id=86668 #cancer_genomics #epigenomics #immunotherapy #precision_oncology #sarcoma #translational_research #tumor_microenvironment #ScienceJobs #hiring #research

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[sisiad]

Pharmacological targeting of the cancer epigenome

http://dlvr.it/T8svDS